We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

83 hedge funds and large institutions have $72.2M invested in TCR2 Therapeutics Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 37 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

221% more call options, than puts

Call options by funds: $1.94M | Put options by funds: $605K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3% less capital invested

Capital invested by funds: $74.8M → $72.2M (-$2.61M)

12% less funds holding

Funds holding: 94 → 83 (-11)

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

70% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 37

Holders
83
Holders Change
-11
Holders Change %
-11.7%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
11
Reduced
37
Closed
23
Calls
$1.94M
Puts
$605K
Net Calls
+$1.34M
Net Calls Change
+$1.4M

Top Buyers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
+$2.66M
2
NM
Newtyn Management
New York
+$1.71M
3
TCM
Tang Capital Management
California
+$1.58M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$749K
5
Millennium Management
Millennium Management
New York
+$540K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.69M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.71M
3
State Street
State Street
Massachusetts
-$1.02M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.01M
5
Prudential Financial
Prudential Financial
New Jersey
-$795K
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$381K +$18.4K +7,442 +6%
KCM
27
Kennedy Capital Management
Missouri
$350K -$2.86K -1,158 -1%
State Street
28
State Street
Massachusetts
$317K -$1.02M -413,838 -79%
Fidelity Investments
29
Fidelity Investments
Massachusetts
$300K -$849 -344 -0.3%
BCM
30
Bridgeway Capital Management
Texas
$285K – – –
Northern Trust
31
Northern Trust
Illinois
$249K -$497K -201,314 -70%
Victory Capital Management
32
Victory Capital Management
Texas
$249K +$2.55K +1,035 +1%
Goldman Sachs
33
Goldman Sachs
New York
$242K -$211K -85,333 -51%
PP
34
PDT Partners
New York
$240K -$200K -81,182 -50%
SSA
35
Schonfeld Strategic Advisors
New York
$187K -$24.7K -10,000 -13%
HCA
36
Harbor Capital Advisors
Illinois
$187K -$7.95K -3,222 -5%
OQS
37
Occudo Quantitative Strategies
Florida
$146K -$41.4K -16,779 -25%
CIC
38
Cornercap Investment Counsel
Georgia
$138K +$117K +47,452 New
MAM
39
Marquette Asset Management
Minnesota
$116K +$17K +6,901 +21%
CSS
40
Cubist Systematic Strategies
Connecticut
$112K -$64K -25,940 -40%
OC
41
Oppenheimer & Co
New York
$109K – – –
PCM
42
Prelude Capital Management
New York
$106K -$42.4K -17,200 -32%
Barclays
43
Barclays
United Kingdom
$103K -$12.2K -4,952 -12%
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
$99K -$6.37K -2,581 -7%
XSC
45
X-Square Capital
Puerto Rico
$93K -$207 -84 -0.3%
Squarepoint
46
Squarepoint
New York
$84K +$71.6K +29,030 New
Qube Research & Technologies (QRT)
47
Qube Research & Technologies (QRT)
United Kingdom
$76K +$64.6K +26,180 New
JMPWA
48
JP Morgan Private Wealth Advisors
California
$74K – – –
Deutsche Bank
49
Deutsche Bank
Germany
$57K +$1.79K +724 +4%
HSBC Holdings
50
HSBC Holdings
United Kingdom
$56K – – –
1
2
3 4 5

TCRR Hedge Fund Activity: Q2 2022 in Review

83 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2022, worth a combined $72.2M — down 3.5% from $74.8M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of TCRR and 14 opened new positions — a net loss of 9 holders — while 37 trimmed existing stakes and 11 added.

The largest buyer was K2 Principal Fund, opening a new position worth an estimated $2.66M. The largest seller was BlackRock, cutting an estimated $3.69M.

  • 83 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2022, down from 94 in Q1 2022.
  • Funds reported $72.2M of TCR2 Therapeutics Inc. Common Stock stock for Q2 2022, down 3.5% quarter-over-quarter.
  • 14 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2022 and 23 closed out, a net change of -9 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q2 2022 was K2 Principal Fund, an estimated $2.66M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $3.69M sold.

Based on aggregated 13F filings for Q2 2022.